|
The Office of Public Affairs, Academia Sinica held an event to present the outcomes of the latest discoveries by researchers at Academia Sinica to prospective business partners on September 24, 2014 from 9:00 am to 12:30 pm.
The event introduced ten of the latest research developments at Academia Sinica. Over 50 representatives from business and industry took part in the event, which helps to build cooperative relationships between the academic community and business sectors.
Among the presentations, Associate Research Fellow, Dr. Chung-Yi Wu from the Genomics Research Center presented a partially purified, fructose-enriched anti-cancer extract of Reishi mushroom. The extract stimulates B-lymphocytes to secrete an antibody to distinguish the tumor-related saccharide antigen and kill lung tumor cells. Moreover, this extract can decrease the amount of tumor-associated inflammatory mediators to achieve shrinkage of lung cancer tumors. Dr. Yi-Chung Chang from the Institute of Biomedical Sciences presented an application of numerous aptamers (small molecules that bind to a specific target molecules) of programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Treatment of cancer patients with the monoclonal antibodies of PD-1 and CTLA-4 are known to improve the process of disease. However, the crucial problems related to monoclonal therapy are the expense and the risk of unwanted immune response. The benefits of these inventions are that they are cheaper than classical monoclonal therapy and do not induce host immune response.
|
